PA
TTNP

Perceptive Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Perceptive Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Hold
0
– – – 200
2016
Q1 		– Sell
-145
Closed -$1.94M – 184
2015
Q4 		$2.32M Buy
+145
New +$2.36M 0.17% 70

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Perceptive Advisors's TTNP Position: Q2 2016 in Review

Perceptive Advisors held its Titan Pharmaceuticals (TTNP) position steady in Q2 2016 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #200.

Perceptive Advisors first reported a position in TTNP in Q4 2015 and has held it in 1 quarter since. The position peaked at $2.32M in Q4 2015. 39 funds tracked by Wall St. Rank hold TTNP as of Q2 2016.

  • Perceptive Advisors held 0 shares of Titan Pharmaceuticals worth $0 as of Q2 2016.
  • Perceptive Advisors left its Titan Pharmaceuticals share count unchanged in Q2 2016.
  • Titan Pharmaceuticals made up ﹤0.01% of Perceptive Advisors's portfolio in Q2 2016, its #200 holding.
  • Perceptive Advisors first reported a position in Titan Pharmaceuticals in Q4 2015 and has held it in 1 quarter since.
  • Perceptive Advisors's Titan Pharmaceuticals position peaked at $2.32M in Q4 2015.
  • 39 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2016.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.